

NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE

HEALTH TECHNOLOGY APPRAISAL PROGRAMME

Equality impact assessment – Guidance development

STA Primary advanced or recurrent endometrial cancer with microsatellite stability or mismatch repair proficiency – dostarlimab with platinum-based chemotherapy

The impact on equality has been assessed during this appraisal according to the principles of the NICE equality scheme.

Consultation

- | | |
|----|--|
| 1. | Have the potential equality issues identified during the scoping process been addressed by the committee, and, if so, how? |
|----|--|

Not relevant. No equality issues identified at scoping.

- | | |
|----|---|
| 2. | Have any other potential equality issues been raised in the submissions, expert statements or academic report, and, if so, how has the committee addressed these? |
|----|---|

Stakeholders highlighted that people from Black ethnic background have a higher incidence of the more aggressive p53 abn subtype of endometrial cancer with MSS or MMRp, which is associated with poorer outcomes. The committee requested further analyses for consideration in the p53-abnormal or TP53 mut subgroups.
--

- | | |
|----|---|
| 3. | Have any other potential equality issues been identified by the committee, and, if so, how has the committee addressed these? |
|----|---|

No.

4.	Do the preliminary recommendations make it more difficult in practice for a specific group to access the technology compared with other groups? If so, what are the barriers to, or difficulties with, access for the specific group?
No.	

5.	Is there potential for the preliminary recommendations to have an adverse impact on people with disabilities because of something that is a consequence of the disability?
No.	

6.	Are there any recommendations or explanations that the committee could make to remove or alleviate barriers to, or difficulties with, access identified in questions 4 or 5, or otherwise fulfil NICE's obligations to promote equality?
No.	

7.	Have the committee's considerations of equality issues been described in the draft guidance, and, if so, where?
Yes, section 3.23.	

Approved by Associate Director (name): Ian Watson

Date: 22 July 2025